Catherine Lhommé

发表

Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2.

Ignace Vergote, Beth Y Karlan, Christian Marth, 2016, Gynecologic oncology.